Fig. 2.

Overexpression of IGF2BP2 predicts poor survival of pancreatic cancer patients. a Representative images of IGF2BP2 staining in pancreatic cancer tissues of various differentiation statuses. Scale bar, 50 μm (red line). b Relative expression score of IGF2BP2 in pancreatic cancer by IHC. c Overexpression of IGF2BP2 was associated with poorer prognosis of PDAC patients of ZZU cohort. d Overexpression of IGF2BP2 was associated with poorer prognosis of PDAC patients in the GSE62452 dataset. e Overexpression of IGF2BP2 was associated with poorer prognosis of PDAC patients in the TCGA dataset. f Frequency (%) of IGF2BP2 genomic alterations in the TCGA cohort. g mRNA expression of IGF2BP2 (RNA Seq V2 RSEM)(log2) plotted against the putative copy-number alterations from GISTIC. h Patients with genomic alterations had poorer survival status. *P < 0.05, **P < 0.01, and ***P < 0.001. P < 0.05 was considered statistically significant